Leishmania donovani-derived lipophosphoglycan plus BCG induces a Th1 type immune response but does not protect Syrian golden hamsters (Mesocricetus auratus) and BALB/c mice against Leishmania donovani

The efficacy of Leishmania donovani-derived lipophosphoglycan (LPG) plus Mycobacterium bovis Bacille Calmette-Guérin (BCG) as a vaccine candidate against visceral leishmaniosis in susceptible BALB/c mouse and Syrian golden hamster (Mesocricetus auratus) models was investigated. Following a triple va...

Full description

Saved in:
Bibliographic Details
Published in:Onderstepoort journal of veterinary research 2003-12, Vol.70 (4), p.255-263
Main Authors: Mbati, P.A., Mkoji, G.M., Tonui, W.K., Mpoke, S.S., Orago, A.S., Turco, S.J.
Format: Article
Language:English
Subjects:
Adjuvants, Immunologic - administration & dosage
Animals
Antibodies, Protozoan - biosynthesis
Bacille Calmette-Guerin
BALBc mice
BCG Vaccine - administration & dosage
BCG Vaccine - immunology
Cricetinae
Cytokines - secretion
Disease Models, Animal
Female
Flow Cytometry
Glycosphingolipids - administration & dosage
Glycosphingolipids - immunology
Hypersensitivity, Delayed
Leishmania donovani
Leishmania donovani - immunology
Leishmaniasis, Visceral - immunology
Leishmaniasis, Visceral - parasitology
Leishmaniasis, Visceral - prevention & control
Lipophosphoglycan
Lymphocyte Activation
Male
Mesocricetus
Mice
Mice, Inbred BALB C
Protozoan Vaccines - administration & dosage
Protozoan Vaccines - immunology
Spleen - parasitology
Syrian golden hamsters
T-Lymphocytes - immunology
Citations: Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:The efficacy of Leishmania donovani-derived lipophosphoglycan (LPG) plus Mycobacterium bovis Bacille Calmette-Guérin (BCG) as a vaccine candidate against visceral leishmaniosis in susceptible BALB/c mouse and Syrian golden hamster (Mesocricetus auratus) models was investigated. Following a triple vaccination with a total dose of 150 µl BCG plus 60 µg or 30 µg of LPG for hamsters and BALB/c mice respectively, there were no noticeable side effects both locally and systemically; implying that the molecule was safe at this dosage level. Vaccinated animals demonstrated an activation of both the humoral as well as cell-mediated responses to LPG, which correlated with resistance against the disease. Protection by LPG plus BCG, was however, poor as the remaining immunized animals showed disease progression leading to severity of the disease as illustrated by emaciation, mass loss and heavy splenic parasitaemia in hamsters. These data nevertheless suggest that it may be rewarding to further evaluate the potential of LPG as a vaccine candidate in leishmaniosis using other adjuvants, which may enhance its immunogenicity.
ISSN:0030-2465
2219-0635
DOI:10.4102/ojvr.v70i4.290